{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:08:32Z","timestamp":1794892112756,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70858-6","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:14:14Z","timestamp":1773944054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["CXCR5+ monocyte emigration impairs the radiation-induced antitumor immune response"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-6790","authenticated-orcid":false,"given":"Yutiantian","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6834-3612","authenticated-orcid":false,"given":"Rui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6887-3659","authenticated-orcid":false,"given":"Mengdi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6382-3815","authenticated-orcid":false,"given":"Mingjun","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruishan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1821-4086","authenticated-orcid":false,"given":"Jiahao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingge","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjun","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0842-3908","authenticated-orcid":false,"given":"Suxia","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"70858_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y. X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365\u2013379 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70858_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Liu, X., Chen, D. & Yu, J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct. Target Ther. 7, 258 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"70858_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","volume":"12","author":"D Schaue","year":"2015","unstructured":"Schaue, D. & McBride, W. H. Opportunities and challenges of radiotherapy for treating cancer. Nat. Rev. Clin. Oncol. 12, 527\u2013540 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70858_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrc2587","volume":"9","author":"GC Barnett","year":"2009","unstructured":"Barnett, G. C. et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat. Rev. Cancer 9, 134\u2013142 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"70858_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang, R. X. & Zhou, P. K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target Ther. 5, 60 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"70858_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0970-x","volume":"18","author":"TB Steinbichler","year":"2019","unstructured":"Steinbichler, T. B. et al. Therapy resistance mediated by exosomes. Mol. Cancer 18, 58 (2019).","journal-title":"Mol. Cancer"},{"key":"70858_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","volume":"84","author":"SC Formenti","year":"2012","unstructured":"Formenti, S. C. & Demaria, S. Radiation therapy to convert the tumor into an in situ vaccine. Int J. Radiat. Oncol. Biol. Phys. 84, 879\u2013880 (2012).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"70858_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & Gogenur, I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"70858_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.immuni.2018.07.008","volume":"49","author":"Y Hou","year":"2018","unstructured":"Hou, Y. et al. Non-canonical NF-kappaB antagonizes STING sensor-mediated DNA sensing in radiotherapy. Immunity 49, 490\u2013503 e494 (2018).","journal-title":"Immunity"},{"key":"70858_CR10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","volume":"30","author":"Y Hou","year":"2024","unstructured":"Hou, Y. et al. Radiotherapy enhances metastasis through immune suppression by inducing PD-L1 and MDSC in distal sites. Clin. Cancer Res 30, 1945\u20131958 (2024).","journal-title":"Clin. Cancer Res"},{"key":"70858_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Investig. 124, 687\u2013695 (2014).","journal-title":"J. Clin. Investig."},{"key":"70858_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01566-5","volume":"8","author":"H Liang","year":"2017","unstructured":"Liang, H. et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat. Commun. 8, 1736 (2017).","journal-title":"Nat. Commun."},{"key":"70858_CR13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria, S., Golden, E. B. & Formenti, S. C. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 1, 1325\u20131332 (2015).","journal-title":"JAMA Oncol."},{"key":"70858_CR14","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell 41, 1294\u20131308 e1298 (2023).","journal-title":"Cancer Cell"},{"key":"70858_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","volume":"35","author":"L Cassetta","year":"2019","unstructured":"Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35, 588\u2013602 e510 (2019).","journal-title":"Cancer Cell"},{"key":"70858_CR16","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2022.8","volume":"24","author":"S Guo","year":"2022","unstructured":"Guo, S., Chen, X., Guo, C. & Wang, W. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy. Expert Rev. Mol. Med. 24, e17 (2022).","journal-title":"Expert Rev. Mol. Med."},{"key":"70858_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162\u2013174 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"70858_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer 21, 28 (2022).","journal-title":"Mol. Cancer"},{"key":"70858_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E. & Tuli, R. Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J. Immunother. Cancer 6, 46 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"70858_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559\u2013572 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"70858_CR21","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.4049\/jimmunol.2100341","volume":"208","author":"J Ren","year":"2022","unstructured":"Ren, J. et al. CXCL13 as a Novel Immune Checkpoint for Regulatory B Cells and Its Role in Tumor Metastasis. J. Immunol. 208, 2425\u20132435 (2022).","journal-title":"J. Immunol."},{"key":"70858_CR22","first-page":"1916","volume":"18","author":"XW Qi","year":"2014","unstructured":"Qi, X. W. et al. Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer. Eur. Rev. Med. Pharm. Sci. 18, 1916\u20131924 (2014).","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"70858_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-013-2811-8","volume":"143","author":"S Biswas","year":"2014","unstructured":"Biswas, S. et al. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res. Treat. 143, 265\u2013276 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"70858_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature12910","volume":"507","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 507, 513\u2013518 (2014).","journal-title":"Nature"},{"key":"70858_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217278","volume":"605","author":"X Gu","year":"2024","unstructured":"Gu, X. et al. Revisiting the CXCL13\/CXCR5 axis in the tumor microenvironment in the era of single-cell omics: Implications for immunotherapy. Cancer Lett. 605, 217278 (2024).","journal-title":"Cancer Lett."},{"key":"70858_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.atherosclerosis.2014.03.021","volume":"234","author":"B Halvorsen","year":"2014","unstructured":"Halvorsen, B. et al. Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. Atherosclerosis 234, 352\u2013359 (2014).","journal-title":"Atherosclerosis"},{"key":"70858_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.bbadis.2018.12.002","volume":"1865","author":"S Biswas","year":"2019","unstructured":"Biswas, S. et al. RelA driven co-expression of CXCL13 and CXCR5 is governed by a multifaceted transcriptional program regulating breast cancer progression. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 502\u2013511 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"70858_CR28","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.immuni.2021.09.018","volume":"54","author":"S Wan","year":"2021","unstructured":"Wan, S. et al. Costimulation molecules differentially regulate the ERK-Zfp831 axis to shape T follicular helper cell differentiation. Immunity 54, 2740\u20132755 e2746 (2021).","journal-title":"Immunity"},{"key":"70858_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-03893-6","volume":"26","author":"T Pan","year":"2022","unstructured":"Pan, T. et al. Immune effects of PI3K\/Akt\/HIF-1alpha-regulated glycolysis in polymorphonuclear neutrophils during sepsis. Crit. Care 26, 29 (2022).","journal-title":"Crit. Care"},{"key":"70858_CR30","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1158\/0008-5472.CAN-22-0507","volume":"82","author":"D Li","year":"2022","unstructured":"Li, D. et al. beta2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages. Cancer Res. 82, 3321\u20133334 (2022).","journal-title":"Cancer Res."},{"key":"70858_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216042","volume":"555","author":"R Palombo","year":"2023","unstructured":"Palombo, R. et al. Inhibition of the PI3K\/AKT\/mTOR signaling promotes an M1 macrophage switch by repressing the ATF3-CXCL8 axis in Ewing sarcoma. Cancer Lett. 555, 216042 (2023).","journal-title":"Cancer Lett."},{"key":"70858_CR32","doi-asserted-by":"publisher","first-page":"iii70","DOI":"10.1136\/ard.2008.098459","volume":"67","author":"T Weichhart","year":"2008","unstructured":"Weichhart, T. & Saemann, M. D. The PI3K\/Akt\/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann. Rheum. Dis. 67, iii70\u2013iii74 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"70858_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri3198","volume":"12","author":"H Chi","year":"2012","unstructured":"Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325\u2013338 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"70858_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"70858_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar, V. et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct. Target Ther. 8, 375 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"70858_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02809-y","volume":"11","author":"K Chen","year":"2020","unstructured":"Chen, K., Zhu, L., Guo, L., Pan, Y. B. & Feng, D. F. Maf1 regulates dendritic morphogenesis and influences learning and memory. Cell Death Dis. 11, 606 (2020).","journal-title":"Cell Death Dis."},{"key":"70858_CR37","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-19-2843","volume":"80","author":"C Porta","year":"2020","unstructured":"Porta, C. et al. Tumor-derived prostaglandin E2 promotes p50 NF-kappaB-dependent differentiation of monocytic MDSCs. Cancer Res. 80, 2874\u20132888 (2020).","journal-title":"Cancer Res."},{"key":"70858_CR38","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148\u20131156 (2022).","journal-title":"Nat. Immunol."},{"key":"70858_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41392-020-0205-z","volume":"5","author":"RD Cervantes-Villagrana","year":"2020","unstructured":"Cervantes-Villagrana, R. D., Albores-Garcia, D., Cervantes-Villagrana, A. R. & Garcia-Acevez, S. J. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct. Target Ther. 5, 99 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"70858_CR40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1517\/14712598.2010.482207","volume":"10","author":"TL Whiteside","year":"2010","unstructured":"Whiteside, T. L. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin. Biol. Ther. 10, 1019\u20131035 (2010).","journal-title":"Expert Opin. Biol. Ther."},{"key":"70858_CR41","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ni943","volume":"4","author":"K Kabashima","year":"2003","unstructured":"Kabashima, K. et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol. 4, 694\u2013701 (2003).","journal-title":"Nat. Immunol."},{"key":"70858_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","volume":"128","author":"KH Parker","year":"2015","unstructured":"Parker, K. H., Beury, D. W. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res 128, 95\u2013139 (2015).","journal-title":"Adv. Cancer Res"},{"key":"70858_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41590-022-01145-x","volume":"23","author":"LN Raines","year":"2022","unstructured":"Raines, L. N. et al. PERK is a critical metabolic hub for immunosuppressive function in macrophages. Nat. Immunol. 23, 431\u2013445 (2022).","journal-title":"Nat. Immunol."},{"key":"70858_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405249","volume":"15","author":"C Li","year":"2024","unstructured":"Li, C. et al. Comprehensive analysis of human monocyte subsets using full-spectrum flow cytometry and hierarchical marker clustering. Front. Immunol. 15, 1405249 (2024).","journal-title":"Front. Immunol."},{"key":"70858_CR45","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00262-020-02701-w","volume":"70","author":"AJ Oweida","year":"2021","unstructured":"Oweida, A. J. et al. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunol. Immunother. 70, 989\u20131000 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"70858_CR46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/bjc.2016.166","volume":"115","author":"V Sridharan","year":"2016","unstructured":"Sridharan, V. et al. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br. J. Cancer 115, 252\u2013260 (2016).","journal-title":"Br. J. Cancer"},{"key":"70858_CR47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.oraloncology.2017.08.007","volume":"73","author":"MS Tsai","year":"2017","unstructured":"Tsai, M. S., Chen, W. C., Lai, C. H., Chen, Y. Y. & Chen, M. F. Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer. Oral. Oncol. 73, 88\u201396 (2017).","journal-title":"Oral. Oncol."},{"key":"70858_CR48","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053\u20132061 (2020).","journal-title":"J. Clin. Oncol."},{"key":"70858_CR49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"HD Kim","year":"2024","unstructured":"Kim, H. D. et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat. Med. 30, 699\u2013707 (2024).","journal-title":"Nat. Med."},{"key":"70858_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 58, 101917 (2023).","journal-title":"EClinicalMedicine"},{"key":"70858_CR51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","volume":"22","author":"SM Lanahan","year":"2022","unstructured":"Lanahan, S. M., Wymann, M. P. & Lucas, C. L. The role of PI3Kgamma in the immune system: new insights and translational implications. Nat. Rev. Immunol. 22, 687\u2013700 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"70858_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A. et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).","journal-title":"Mol. Cancer"},{"key":"70858_CR53","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-025-08994-0","volume":"643","author":"A Piffko","year":"2025","unstructured":"Piffko, A. et al. Radiation-induced amphiregulin drives tumour metastasis. Nature 643, 810\u2013819 (2025).","journal-title":"Nature"},{"key":"70858_CR54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222\u2013225 (2011).","journal-title":"Nature"},{"key":"70858_CR55","doi-asserted-by":"publisher","unstructured":"Lucotti, S. et al. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell, https:\/\/doi.org\/10.1016\/j.cell.2025.01.025 (2025).","DOI":"10.1016\/j.cell.2025.01.025"},{"key":"70858_CR56","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10238-024-01508-8","volume":"24","author":"L Hui","year":"2024","unstructured":"Hui, L., Li, Y., Huang, M. K., Jiang, Y. M. & Liu, T. CXCL13: a common target for immune-mediated inflammatory diseases. Clin. Exp. Med. 24, 244 (2024).","journal-title":"Clin. Exp. Med."},{"key":"70858_CR57","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jhep.2019.09.031","volume":"72","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection. J. Hepatol. 72, 420\u2013430 (2020).","journal-title":"J. Hepatol."},{"key":"70858_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf5464","volume":"9","author":"F Wang","year":"2023","unstructured":"Wang, F. et al. Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer. Sci. Adv. 9, eadf5464 (2023).","journal-title":"Sci. Adv."},{"key":"70858_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01990-3","volume":"22","author":"ZX Wu","year":"2024","unstructured":"Wu, Z. X. et al. CD69(+)CD103(+)CD8(+) tissue-resident memory T cells possess stronger anti-tumor activity and predict better prognosis in colorectal cancer. Cell Commun. Signal 22, 608 (2024).","journal-title":"Cell Commun. Signal"},{"key":"70858_CR60","doi-asserted-by":"publisher","unstructured":"Ni, H. et al. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. Nat. Cancer, https:\/\/doi.org\/10.1038\/s43018-025-00905-6 (2025).","DOI":"10.1038\/s43018-025-00905-6"},{"key":"70858_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo, S. et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct. Target Ther. 8, 205 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"70858_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","volume":"21","author":"ME Rodriguez-Ruiz","year":"2020","unstructured":"Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I. & Galluzzi, L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat. Immunol. 21, 120\u2013134 (2020).","journal-title":"Nat. Immunol."},{"key":"70858_CR63","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00066-023-02172-9","volume":"200","author":"F Gregucci","year":"2024","unstructured":"Gregucci, F. et al. Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma. Strahlenther. Onkol. 200, 751\u2013759 (2024).","journal-title":"Strahlenther. Onkol."},{"key":"70858_CR64","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fonc.2019.00624","volume":"9","author":"A Kennedy","year":"2019","unstructured":"Kennedy, A. et al. Regorafenib prior to selective internal radiation therapy using (90)Y-resin microspheres for refractory metastatic colorectal cancer liver metastases: analysis of safety, dosimetry, and molecular markers. Front. Oncol. 9, 624 (2019).","journal-title":"Front. Oncol."},{"key":"70858_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1274487","volume":"13","author":"S Zhou","year":"2023","unstructured":"Zhou, S. et al. Regorafenib alone or in combination with high\/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT). Front. Oncol. 13, 1274487 (2023).","journal-title":"Front. Oncol."},{"key":"70858_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/0284186X.2020.1871067","volume":"60","author":"G Bregni","year":"2021","unstructured":"Bregni, G. et al. Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer. Acta Oncol. 60, 549\u2013553 (2021).","journal-title":"Acta Oncol."},{"key":"70858_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-024-03337-2","volume":"26","author":"S Cohen","year":"2024","unstructured":"Cohen, S. et al. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics\/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Res. Ther. 26, 117 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"70858_CR68","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/neuonc\/noac070","volume":"24","author":"E Le Rhun","year":"2022","unstructured":"Le Rhun, E. et al. Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. Neuro Oncol. 24, 1533\u20131545 (2022).","journal-title":"Neuro Oncol."},{"key":"70858_CR69","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","volume":"31","author":"P Mauch","year":"1995","unstructured":"Mauch, P. et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 31, 1319\u20131339 (1995).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"70858_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350836","volume":"54","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. Trappc1 intrinsically prevents ferroptosis of naive T cells to avoid spontaneous autoinflammatory disease in mice. Eur. J. Immunol. 54, e2350836 (2024).","journal-title":"Eur. J. Immunol."},{"key":"70858_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34431-1","volume":"13","author":"L Gong","year":"2022","unstructured":"Gong, L. et al. CK2-mediated phosphorylation of SUZ12 promotes PRC2 function by stabilizing enzyme active site. Nat. Commun. 13, 6781 (2022).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70858-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70858-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70858-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:02:48Z","timestamp":1778760168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70858-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70858"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70858-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4258"}}